Clinical Report: Retrospective Analysis of Immune-Related Hepatitis Linked to Pembrolizumab
Overview
This report analyzes 42 case reports of pembrolizumab-induced immune-related hepatitis, highlighting patient demographics, clinical manifestations, and treatment strategies. The findings emphasize the need for careful monitoring of liver function in patients receiving pembrolizumab.
Background
Immune checkpoint inhibitors (ICIs) like pembrolizumab are widely used in cancer treatment but can cause immune-related adverse events (irAEs), including hepatitis. Understanding the characteristics and management of pembrolizumab-induced hepatitis is essential for improving patient safety and treatment outcomes.
Data Highlights
Characteristic
Data
Number of cases
42
Male patients
27
Female patients
14
Average age
64.2 years
Shortest time to onset
2 days
Longest time to onset
630 days
Primary treatment
Corticosteroids
Key Findings
Clinical manifestations included liver toxicity, neurological symptoms, skin reactions, systemic symptoms, and digestive symptoms.
The onset of immune-related hepatitis varied significantly among patients.
Corticosteroids were the primary treatment for managing immune-related hepatitis.
Pathogenesis may involve dysregulation of liver immune tolerance.
Regular monitoring of liver function is recommended during pembrolizumab treatment.
Clinical Implications
Clinicians should evaluate liver function and history of liver disease before initiating pembrolizumab. Continuous monitoring during treatment is crucial to manage any liver abnormalities promptly.
Conclusion
The analysis of pembrolizumab-induced immune-related hepatitis highlights the importance of monitoring and understanding this adverse effect to enhance patient safety and treatment efficacy.
